Summary
Stroke is the 2nd cause of death and major handicaps in industrialized countries. At present, the only available treatment for ischemic stroke are thrombolysis and thrombectomy. However, very few patients are eligible, and it is therefore absolutely urgent to find an alternative.
RGTA® are synthetic polysaccharides, mimicking endogenous macro-molecules called heparan sulphates, that make up the biological networks in which our cells live and reproduce: the extracellular matrix.
We have recently investigated the neuroprotective potential of a novel specific RGTA® (OTR4132) at the preclinical level using a rodent model of transient focal cerebral ischemia The i.v. administration of OTR4132-MD elicited a reduction of 39,6% of the volume of infarction at 48 hours following the insult. Interestingly, this RGTA®-induced reduction of brain damage persisted up to the chronic stage and RGTA®-treated animals showed a significant improvement of functional recovery (motor and sensorial) when compared to control animals.
Translational stroke studies in rodent models have thus already demonstrated the beneficial effects of RGTA® in acute phase and, following additional preclinical studies in an independent laboratory, the project will be ready for next stages of its route to market introduction, including clinical validation and product registration. The objective of the SMR project is to translate experimental findings into medical innovation, leading to a quick benefit for stroke patients. Positive outcomes of the project will lead rapidly to the EU registration of OTR4132-MD injectable solution as a medical device or a drug and to its market introduction in Europe for the stroke indication.
RGTA® are synthetic polysaccharides, mimicking endogenous macro-molecules called heparan sulphates, that make up the biological networks in which our cells live and reproduce: the extracellular matrix.
We have recently investigated the neuroprotective potential of a novel specific RGTA® (OTR4132) at the preclinical level using a rodent model of transient focal cerebral ischemia The i.v. administration of OTR4132-MD elicited a reduction of 39,6% of the volume of infarction at 48 hours following the insult. Interestingly, this RGTA®-induced reduction of brain damage persisted up to the chronic stage and RGTA®-treated animals showed a significant improvement of functional recovery (motor and sensorial) when compared to control animals.
Translational stroke studies in rodent models have thus already demonstrated the beneficial effects of RGTA® in acute phase and, following additional preclinical studies in an independent laboratory, the project will be ready for next stages of its route to market introduction, including clinical validation and product registration. The objective of the SMR project is to translate experimental findings into medical innovation, leading to a quick benefit for stroke patients. Positive outcomes of the project will lead rapidly to the EU registration of OTR4132-MD injectable solution as a medical device or a drug and to its market introduction in Europe for the stroke indication.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/811729 |
| Start date: | 01-10-2018 |
| End date: | 31-05-2024 |
| Total budget - Public funding: | 3 404 200,00 Euro - 2 382 940,00 Euro |
Cordis data
Original description
Stroke is the 2nd cause of death and major handicaps in industrialized countries. At present, the only available treatment for ischemic stroke are thrombolysis and thrombectomy. However, very few patients are eligible, and it is therefore absolutely urgent to find an alternative.RGTA® are synthetic polysaccharides, mimicking endogenous macro-molecules called heparan sulphates, that make up the biological networks in which our cells live and reproduce: the extracellular matrix.
We have recently investigated the neuroprotective potential of a novel specific RGTA® (OTR4132) at the preclinical level using a rodent model of transient focal cerebral ischemia The i.v. administration of OTR4132-MD elicited a reduction of 39,6% of the volume of infarction at 48 hours following the insult. Interestingly, this RGTA®-induced reduction of brain damage persisted up to the chronic stage and RGTA®-treated animals showed a significant improvement of functional recovery (motor and sensorial) when compared to control animals.
Translational stroke studies in rodent models have thus already demonstrated the beneficial effects of RGTA® in acute phase and, following additional preclinical studies in an independent laboratory, the project will be ready for next stages of its route to market introduction, including clinical validation and product registration. The objective of the SMR project is to translate experimental findings into medical innovation, leading to a quick benefit for stroke patients. Positive outcomes of the project will ultimately lead to the EU registration of OTR4132-MD injectable solution as a medical device or a drug and to its market introduction in Europe for the stroke indication.
Status
SIGNEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
